Study of a new antibody treatment for frequent genital herpes outbreaks
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an investigational medication called UB-621, given as repeated doses, to see if it is safe and effective in reducing recurrent genital herpes outbreaks in adults. If you have frequent outbreaks (6 to 12 per year), this trial might help you find a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have tested positive for HSV-2, the virus that causes genital herpes.
- You have had 6 to 12 genital herpes outbreaks in the past year.
- You are HIV-negative and have no other conditions in the genital area that could interfere with the study.
- You are willing to come to the study site within 3 days (72 hours) of a new outbreak and keep a daily diary during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
This trial tests whether a medicine called acyclovir can prevent herpes simplex outbreaks in people who also have an autoimmune rheumatic disease. It may help reduce the number of painful cold sores or genital herpes episodes you experience.
This trial tests whether 2LHERP® can reduce or manage frequent herpes infections around the mouth. It compares the study drug to a placebo (inactive treatment) in people who get many episodes each year.
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
This trial offers a new antiviral medicine called pritelivir to people with weakened immune systems who have herpes sores that do not get better with standard treatments. Taking pritelivir may help clear these resistant sores when other options have failed.
Hear when a new Recurrent Genital Herpes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.